Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASR | P41180 | 15/20 | 0.55 |
| ▸ | WDR5 | P61964 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | NSD2 | O96028 | 1/20 | 0.32 |
| ▸ | MMP14 | P50281 | 1/20 | 0.32 |
| ▸ | CASP6 | P55212 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | ACLY | P53396 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14471541 | 0.81 | CASR (0.56) | CASRHPGDALOX15ACLY | |
| SCHEMBL14471683 | 0.81 | CASR (0.56) | CASRHPGDALOX15ACLY | |
| SCHEMBL14877427 | 0.77 | CASR (0.67) | CASR | |
| SCHEMBL6005143 | 0.77 | CASR (0.67) | CASR | |
| SCHEMBL14791493 | 0.76 | CASR (0.69) | CASRACLY | |
| SCHEMBL176932 | 0.76 | CASR (0.66) | CASR | |
| SCHEMBL14471538 | 0.75 | CASR (0.69) | CASRACLY | |
| SCHEMBL14471571 | 0.74 | CASR (0.66) | CASRACLY | |
| SCHEMBL18469096 | 0.74 | CASR (0.66) | CASRACLY | |
| SCHEMBL14471569 | 0.74 | CASR (0.66) | CASRACLY |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9561216-B2 | Alkylamine derivative | EA PHARMA CO., LTD. (JP) | 2017-02-07 | — | — | US | disclosed |
| US-20160101091-A1 | ALKYLAMINE DERIVATIVE | AJINOMOTO CO., INC. (JP) | 2016-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160101091-A1 | ALKYLAMINE DERIVATIVE | CASR, TAAR5, TAAR1 | CASR 1/4885WDR5 2676/4885KDM4E 2311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.